C. Visseren-Grul

发表

Final Efficacy and Safety Results of Pemetrexed Continuation Maintenance Therapy in the Elderly from the PARAMOUNT Phase III Study

C. Gridelli, Michael Thomas, F. de Marinis, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic Study

J. Schellens, H. Rosing, J. Beijnen, 2008, Clinical Cancer Research.

Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.

R. Ramlau, M. Krzakowski, A. Santoro, 2012, The Lancet. Oncology.

A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer.

S. Novello, P. Zatloukal, N. Iscoe, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent.

D. Amadori, R. Stahel, S. Siena, 2009, Lung cancer.

Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer.

G. Hillerdal, M. Nicolson, Y. Summers, 2015, Lung cancer.

Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY

J. Shih, Keunchil Park, C. Chiu, 2020, Cancer science.

RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC

K. Nishio, S. Ikeda, A. Zimmermann, 2022, JTO clinical and research reports.

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

J. Shih, Keunchil Park, S. Novello, 2019, The Lancet. Oncology.

RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability

J. Shih, S. Novello, M. Reck, 2021, Drug Safety.

Bevacizumab combined with pemetrexed plus cisplatin followed by maintenance bevacizumab/pemetrexed as first-line treatment of advanced non-squamous non-small cell lung cancer: A single-arm Phase 2 study

G. Hillerdal, A. Santoro, A. Favaretto, 2014 .

A Phase II Randomized Study of Cisplatin-Pemetrexed plus either Enzastaurin or Placebo in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer

R. Ramlau, J. von Pawel, C. Eschbach, 2012, Oncology.

Pemetrexed use in the adjuvant setting for completely resectable non-small-cell lung cancer.

C. Obasaju, G. Simon, C. Manegold, 2013, Clinical lung cancer.

Reply to S. Barni et Al, K.R. Dearing et al, and N. Murray.

C. Gridelli, F. de Marinis, L. Paz-Ares, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association between Gene Expression Profiles and Clinical Outcome of Pemetrexed-Based Treatment in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Exploratory Results from a Phase II Study

Tuan S. Nguyen, P. Maxwell, K. Kerr, 2014, PloS one.

Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study.

G. Scagliotti, Keunchil Park, S. Gans, 2009, European journal of cancer.

Phase II study of gemcitabine in ovarian cancer.

T. Bauknecht, J. Neijt, G. von Minckwitz, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship

R. Walgren, A. Zimmermann, Ling Gao, 2022, Cancer Chemotherapy and Pharmacology.

A phase III randomized study of surgery alone or surgery plus preoperative gemcitabine-cisplatin in early-stage non-small cell lung cancer (NSCLC): Follow-up data of Ch.E.S.

V. Torri, G. Scagliotti, M. Hetzel, 2008 .

Phase I and pharmacologic study of enzastaurin HCl, gemcitabine and cisplatin.

J. Schellens, J. Beijnen, E. Voest, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PLS. plenary session

C. Obasaju, C. Gridelli, L. Sequist, 2012 .

Non-small cell lung cancer, locally advanced

P. Lambin, S. Kozlov, I. Petersen, 2012 .

Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non e Small-Cell Lung Cancer

C. Gridelli, L. Paz-Ares, J. Pujol, 2014 .

Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study.

E. Smit, P. Schnabel, J. Aerts, 2015, Lung cancer.

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

P. Albers, M. Moore, I. Bodrogi, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship

R. Walgren, A. Zimmermann, Ling Gao, 2022, Cancer Chemotherapy and Pharmacology.

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset

Y. Ohe, K. Kiura, K. Goto, 2021, JTO clinical and research reports.

1298P RELAY, ramucirumab plus erlotinib (RAM+ERL) versus placebo plus erlotinib (P+ERL) in untreated EGFR mutated metastatic non-small cell lung cancer (NSCLC): Exposure-response relationship

R. Walgren, A. Zimmermann, Ling Gao, 2020 .

P3.01-75 RELAY+, an Exploratory Study of Gefitinib with Ramucirumab in Untreated Patients with EGFR Mutation-Positive Metastatic NSCLC

K. Nishio, K. Suzukawa, M. Nishio, 2018, Journal of Thoracic Oncology.

Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup

P. Giraud, S. Novello, U. Ricardi, 2017, ESMO Open.

TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

M. Rizzo, Yongmei Chen, X. Le, 2022, Cancers.

Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer.

D. Fennell, D. Ferry, Y. Summers, 2016, Cancer treatment reviews.

Dual EGFR/VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC.

X. Le, J. Goldman, M. Reck, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program

K. Nackaerts, R. Stahel, A. Santoro, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

C. Gridelli, F. de Marinis, L. Paz-Ares, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.

C. Gridelli, Michael Thomas, F. de Marinis, 2012, The Lancet. Oncology.

Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer

L. Paz-Ares, C. Visseren-Grul, J. C. Jaime, 2010, BMC Cancer.

Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer

K. Yoh, D. Moro-Sibilot, A. Zimmermann, 2020, Current medical research and opinion.

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer

J. Shih, Keunchil Park, L. Paz-Ares, 2021, Clinical Cancer Research.

PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

C. Gridelli, Michael Thomas, F. de Marinis, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer.

V. Torri, G. Scagliotti, M. Hetzel, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer.

G. Scagliotti, C. Gridelli, C. Langer, 2012, Clinical lung cancer.

A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer.

Tuan S. Nguyen, W. Engel-Riedel, J. Mazières, 2015, Lung cancer.

Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer.

G. Scagliotti, J. von Pawel, J. Vansteenkiste, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

C5-01: Open-label study of pemetrexed alone or in combination with a platinum in chemonaïve patients (pts) with malignant pleural mesothelioma (MPM): Results from the International Expanded Access Program (EAP)

K. Nackaerts, R. Stahel, A. Santoro, 2007 .

Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design

G. Hillerdal, M. Nicolson, C. Visseren-Grul, 2013, Health and Quality of Life Outcomes.

Safety and Resource Utilization by Non-small Cell Lung Cancer Histology: Results from the Randomized Phase III Study of Pemetrexed Plus Cisplatin versus Gemcitabine Plus Cisplatin in Chemonaïve Patients with Advanced Non-small Cell Lung Cancer

S. Novello, J. von Pawel, L. Paz-Ares, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.

Nick Thatcher, Shengyan Hong, Jacek Jassem, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C β-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer

J. Schellens, J. Beijnen, E. Voest, 2007, Clinical Cancer Research.

Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non–Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial

Tuan S. Nguyen, K. O'Byrne, K. Kerr, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized Double-Blind Phase II Trial Comparing Gemcitabine Plus LY293111 Versus Gemcitabine Plus Placebo in Advanced Adenocarcinoma of the Pancreas

H. Oettle, W. Vervenne, M. Saif, 2009, Cancer journal.

RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome.

S. Novello, L. Paz-Ares, M. Nishio, 2023, Clinical lung cancer.

Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study.

E. Smit, P. Schnabel, J. Aerts, 2015, Lung cancer.

RELAY+: Exploratory study of ramucirumab plus gefitinib in untreated patients (pts) with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell lung cancer (NSCLC).

K. Nishio, S. Ikeda, A. Zimmermann, 2020 .

Safety, Resource Use, and Quality of Life in Paramount: A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

C. Gridelli, F. de Marinis, R. Ramlau, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with EGFR exon 19 deletions or exon 21 mutations.

Yongmei Chen, M. Leusch, C. Visseren-Grul, 2021, Future oncology.

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis.

S. Novello, D. Moro-Sibilot, A. Zimmermann, 2021, Cancer treatment and research communications.

Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.

G. Scagliotti, C. Gridelli, F. de Marinis, 2014, Lung cancer.

Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational study

E. Smit, D. Moro-Sibilot, S. Schmitz, 2010, Current medical research and opinion.

Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment pathways from the SELECTTION observational study

E. Smit, D. Moro-Sibilot, S. Schmitz, 2012, Current medical research and opinion.

Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer.

Tuan S. Nguyen, K. Syrigos, F. Mayer, 2013, Lung cancer.

Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC).

P. Giraud, S. Novello, U. Ricardi, 2015, Lung cancer.

RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: outcomes by EGFR mutation type

T. Seto, M. Reck, E. Nadal, 2020, Pneumologie.

Randomized double-blind phase II trial comparing gemcitabine (GEM) plus LY293111 vs. GEM plus placebo in advanced adenocarcinoma of the pancreas

H. Oettle, W. Vervenne, M. Saif, 2005 .

Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

C. Gridelli, F. de Marinis, R. Ramlau, 2018, Current medical research and opinion.

I. Bodrogi, P. Conte, L. Dogliotti, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study.

E. Smit, J. Aerts, D. Moro-Sibilot, 2016, Lung cancer.

Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

C. Gridelli, Michael Thomas, F. de Marinis, 2014, Clinical lung cancer.

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.

I. Bodrogi, P. Conte, H. von der Maase, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results

M. Nishio, M. Reck, E. Garon, 2023, ESMO open.

Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review

E. Garon, C. Visseren-Grul, Martin Reck, 2023, Frontiers in Oncology.

C. Gridelli, F. de Marinis, R. Ramlau, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pemetrexed plus cisplatin (P+Cis) or pemetrexed plus carboplatin (P+Cb) for chemonaive patients (pts) with malignant pleural mesothelioma (MPM): Results of the International Expanded Access Program (EAP)

K. Nackaerts, R. Stahel, A. Santoro, 2007 .

C. Gridelli, Michael Thomas, F. de Marinis, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

L. Paz-Ares, C. Visseren-Grul, J. C. Jaime, 2010, BMC Cancer.